跳至主要内容
临床试验/NCT01161407
NCT01161407已完成不适用

Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease

Indiana University1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2010年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
12
试验地点
1
主要终点
Calcium Balance

研究概览

简要总结

The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD) using calcium balance and kinetic methods.

详细描述

The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD). It is important that the body get enough calcium to support many important body functions including bone health. CKD changes the calcium balance or how calcium is absorbed and excreted. Because of this, the knowledge of calcium absorption and excretion in patients with normal kidney function cannot be used to assess patients with CKD. In patients with CKD bone heath is often negatively affected due to a combination of poor calcium absorption, increased bone turnover (process where old bone is removed and new bone is formed), increased level of parathyroid hormone (PTH [ a hormone that acts to increase calcium in the blood]) and decrease in vitamin D levels. This negative effect is referred to as Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD).

Treatment to correct CKD-MBD should begin early in the course of CKD. In the normal population calcium supplements are frequently used to help prevent age related bone loss. Calcium supplements can also be used in CKD patients to help bind phosphate. Maintaining correct levels of phosphate in the body is crucial in CKD. However, calcium supplements may have adverse effects by promoting calcium phosphate deposits in soft tissues like the vascular system which could increase the risk of cardiovascular disease.

Therefore this formal balance study is needed to determine if positive calcium balance occurs in patients with advanced CKD who are given calcium with meals as a phosphate binder. This study will also evaluate how the body handles phosphate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients with a GFR of < 45 ml/min;
  • •Intact serum PTH > 37 pg/ml;
  • •Age > 35 years (both genders and all races);
  • •Able to perform two three-week balance studies;
  • •Not on oral calcium or vitamin D other than multi vitamin, or willing to stop calcium or vitamin D for one month prior to entry in the study (day 1 of first calcium balance period);
  • •Female patients must be post-menopausal (defined as last menstrual period at least 12 months prior to screening visit) or surgically sterile by hysterectomy;
  • •On stable doses of diuretics, bisphosphonates, anti-epileptics (except dilantin) for at least 2 months.

排除标准

  • •Serious underlying systemic disease (including uncontrolled diabetes, lupus, hypertension, amyloid, etc);
  • •Taking drugs that alter calcium and phosphate balance or homeostasis including high dose cholecalciferol or ergocalciferol (1000 U/day or 50,000U/ wk, respectively), active vitamin D metabolites, calcimimetics, PTH analogues in the last 30 days;
  • •Taking drugs that the investigator feels will alter calcium balance;
  • •Plan to initiate dialysis in the next six months;
  • •Hypercalcemia defined as serum calcium > 10.5 mg/dl;
  • •Hyperphosphatemia defined as serum phosphate >5.5mg/ml;
  • •Intestinal disease that alters absorption or normal intestinal function including celiac disease, small bowel resection, bariatric surgery;

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.

干预措施: Placebo (Dietary Supplement)

Calcium Carbonate (Phosphate Binder)

Active Comparator

500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.

干预措施: 1500 mg/d elemental calcium as calcium carbonate (Dietary Supplement)

结局指标

主要结局

Calcium Balance

时间窗: 2 weeks

Calcium balance is measured by dietary calcium intake (mg/d) minus calcium excretion (mg/d) (from both urine and feces).

次要结局

  • Phosphorus Balance(2 weeks)
  • "Bone Balance" From Calcium Kinetics(2 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Munro Peacock

Professor

Indiana University

研究点 (1)

Loading locations...

相似试验